Printer Friendly

Adaptive Biotechnologies and Collaborators Present 13 Studies Demonstrating Clinical Relevance of Immunosequencing at 56th Annual Meeting of the American Society for Hematology.

Data Validates Clinical Advantage of Tracking Minimal Residual Disease with the clonoSEQ(TM) Test in Patients with ALL, CLL, MM, DLBCL

Quantitative Assessment of T Cell Repertoire Diversity by immunoSEQ(TM) Informs Cord Blood and Solid Organ Transplantation

SEATTLE, Dec. 2, 2014 /PRNewswire/ -- Adaptive Biotechnologies, the pioneer of Next Generation Sequencing (NGS) of the adaptive immune system, and its collaborators will present data demonstrating how immunosequencing can inform clinical care in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 6-9, 2014.

Immunosequencing is an emerging field where NGS technology is specifically tailored to sequence T and B cell receptors, enabling an in-depth characterization of the adaptive immune response.

The clonoSEQ(TM) Test is a clinically validated, CLIA-certified diagnostic used to monitor Minimal Residual Disease (MRD), the cancerous cells remaining after treatment, in patients with T and B cell malignancies. The technology tracks a single clone that acts as a genetic "tag" of a leukemia or lymphoma. Flow cytometry is the current standard for tracking MRD, but the technique can be inaccurate and difficult to standardize.

At ASH, data will be presented that explores the potential correlation between greater sensitivity of MRD detection using clonoSEQ and clinical outcome in patients with different types of blood cancers including Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Diffuse Large B Cell Lymphoma (DLBCL). In particular, data will demonstrate how the clonoSEQ Test was used to confirm efficacy of a CAR T Cell Therapy for patients with B-cell ALL. Additionally, data will be presented highlighting the potential use of the clonoSEQ Test in the diagnoses of certain types of lymphoma, including Cutaneous T Cell Lymphoma (CTCL).

"The array of data being presented at ASH this year demonstrates the wide applicability of the clonoSEQ Test for the diagnosis, prognosis, and monitoring of patients with lymphoid malignancies," says Dr. Harlan Robins, Scientific Founder of Adaptive Biotechnologies. "Our clinical experience over the past twelve months confirms the importance of the reliability and sensitivity that the clonoSEQ Test offers hematologists."

Additionally at ASH, Adaptive and its collaborators will present data from studies utilizing the immunoSEQ(TM) Assay, the company's research-based immunosequencing platform, to monitor the immune repertoire of patients who have received blood or organ transplants. These studies show how the immunoSEQ Assay can be used to determine whether patients are at risk of infection or rejection early on, potentially allowing physicians to change course of care.

"Adaptive is at the forefront of a paradigm shift in the diagnosis and monitoring of patients with blood cancers," says Chad Robins, CEO and Founder of Adaptive Biotechnologies. "We are working with leading hematology scientific advisors globally to ensure the diagnostic and monitoring benefits offered by the immunosequencing are made more readily available to patients."

Adaptive representatives will be onsite in the exhibition hall (booth #225) to answer questions about its immunosequencing technology.

Oral presentations highlighting the utility of clonoSEQ in CART-19 and Transplantation:

Abstract #192: Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation Presenter: Nicoletta Cieri Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Risk Factors for GVHD and Outcomes Time: Sunday, December 7, 2014: 4:30 PM-6:00 PM (Oral presentation at 5:10pm) Location: West Building, 3009-3011-3022-3024 (Moscone Center)

Abstract #191: Immune Reconstitution in Recipients of Living Donor Kidney/Hematopoietic Stem + Facilitating Cell Transplants Presenter: Joseph Leventhal Session: 722. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Risk Factors for GVHD and Outcomes Time: Sunday, December 7, 2014: 4:30 PM-6:00 PM ( Oral presentation at 5:02pm) Location: West Building, 3009-3011-3022-3024 (Moscone Center)

Abstract # 382: CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL Presenter: Jae Park Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Immunotherapeutic Trials in ALL Time: Monday, December 8, 2014: 10:30 AM-12:00 PM ( Oral presentation at 11:15am) Location: West Building, 3009-3011-3022-3024 (Moscone Center)

Presentations highlighting the utility of clonoSEQ for monitoring and diagnosis:

Abstract #1683: High Throughput TCR Sequencing Provides Added Value in the Diagnosis of Cutaneous T-Cell Lymphoma Presenter: Ilan Kirsch Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM Location: West Building, Level 1 (Moscone Center)

Abstract #1669: Defining Immunoglobulin Somatic Hypermutation in De Novo Diffuse Large B-Cell Lymphoma Patients: Potential Application for Prognosis and Risk Stratification Presenter: Ilan Kirsch Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM Location: West Building, Level 1 (Moscone Center)

Abstract #1976: A Complementary Role of High Throughput Sequencing and Multiparameter Cytometry for Minimal Residual Disease (MRD) Detection in Chronic Lymphocytic Leukemia (CLL):an European Research Initiative (ERIC) Study Presenter: Andy Rawstron Session: 641. CLL: Biology and Pathophysiology, excluding Therapy: Poster I Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM Location: West Building, Level 1 (Moscone Center)

Abstract #1687: Next Generation Sequencing of B Cell Antigen Receptors Expressed in African Endemic Burkitt Lymphoma Presenter: Katharine Lombardo Session: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Poster I Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM Location: West Building, Level 1 (Moscone Center)

Abstract #2399: Minimal Residual Disease Detection By Next Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia (ALL) Patients Treated on SWOG Trial S0333 Presenter: Olga Sala Torra Session: 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Poster II Time: Sunday, December 7, 2014: 6:00 PM-8:00 PM Location: North Building, Hall E (Moscone Center)

Abstract #2544: Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and Sezary Syndrome (SS) Presenter: Wen-Kai Weng Session: 732. Clinical Allogeneic Transplantation: Results: Poster II Time: Sunday, December 7, 2014: 6:00 PM-8:00 PM Location: North Building, Hall E (Moscone Center)

Abstract #3413: Detection of the Malignant B Cell Clone in Multiple Myeloma Via High Throughput Sequencing Is Robust to Significant Levels of Somatic Hypermutation Presenter: Christopher Carlson Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster II Time: Sunday, December 7, 2014: 6:00 PM-8:00 PM Location: West Building, Level 1 (Moscone Center)

Abstract #3711: T Cell Products of Defined CD4:CD8 Composition and Prescribed Levels of CD19CAR/Egfrt Transgene Expression Mediate Regression of Acute Lymphoblastic Leukemia in the Setting of Post-Allohsct Relapse Presenter: Rebecca Gardner Session: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Poster III Time: Monday, December 8, 2014: 6:00 PM-8:00 PM Location: North Building, Hall E (Moscone Center)

Additional presentations highlighting the utility of clonoSEQ in transplantation:

Abstract #1262: TCR Repertoire Diversity Assessed with Immunosequencing Is Associated with Patient Mortality Following Cord Blood Transplant Presenter: Ryan Emerson Session: 732. Clinical Allogeneic Transplantation: Results: Poster I Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM Location: North Building, Hall E (Moscone Center)

Abstract #2473: Use of High-Throughput Sequencing (HTS) of TCRE to Determine the Kinetics of Graft-Versus-Lymphoma (GVL) Effect and T-Cell Repertoire Profiles after Allogeneic Transplant Presenter: Wen-Kai Weng Session: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities: Poster II Time: Sunday, December 7, 2014: 6:00 PM-8:00 PM Location: North Building, Hall E (Moscone Center)

About Adaptive Biotechnologies Adaptive Biotechnologies Corporation is a platform-based, diagnostic-driven company that leverages NGS to profile T-Cell and B-Cell Receptors. This breakthrough enables in-depth characterization of the adaptive immune system, which is the primary defense against cancer. By incorporating immunosequencing into clinical care, Adaptive can enhance the diagnosis, prognosis and monitoring of cancer patients.

About immunoSEQ(TM) Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ(TM) brand name. The immunoSEQ(TM) Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.

About clonoSEQ(TM) Adaptive uses its proprietary immunosequencing platform to validate clinical diagnostics in cancer and other immune-mediated diseases. The company's first CLIA certified clinical application, the clonoSEQ(TM) Assay, is used to monitor Minimal Residual Disease (MRD) in blood-based cancers. Improving the ability to accurately detect and track residual disease at a molecular level affords clinicians the potential to detect relapse earlier and improve patient care.

The company is currently validating the tilSEQ(TM) Assay, a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes ("TILs") and to create a reliable measure of "immunocompetency" to predict or monitor response to cancer treatments that directly alter the host immune system.

Logo - http://photos.prnewswire.com/prnh/20120103/SF28632LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/adaptive-biotechnologies-and-collaborators-present-13-studies-demonstrating-clinical-relevance-of-immunosequencing-at-56th-annual-meeting-of-the-american-society-for-hematology-300002996.html</a>

SOURCE Adaptive Biotechnologies
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 2, 2014
Words:1967
Previous Article:Vaccinex and Janssen enter into a collaboration for the creation of novel anti-cancer agents.
Next Article:CRH Medical Announces Significant Acquisition.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters